Literature DB >> 14742278

Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.

Shang-Yi Huang1, Hwei-Fang Tien, Fang-Hsein Su, Su-Ming Hsu.   

Abstract

The NOD/SCID human chimeric animal model was generated by implanting of human fetal bones (FBs) into subcutaneous sites of NOD/SCID mice (NOD/SCID-hu(+)), followed by inoculation of primary bone marrow mononuclear cells (BMNCs) obtained from patients with multiple myeloma (MM) into the FBs. The BMNCs from 30 patients with MM were inoculated, and 28 (93%) of them revealed evidence of tumor growth of myeloma cells (MCs) in the NOD/SCID-hu(+) mice. Intriguingly, 17 (61%) of the 28 patients' BMNCs inoculated developed not only myeloma in the bone marrow of the FBs, but also extramedullary macrotumors (EMTs) along the periosteum of the FBs. The tumor cells in these EMTs had plasmacytoid morphology and preserved antigens and cytogenetics similar, if not identical, to those in the parent MCs. Moreover, small tumor blocks from nine EMTs were transplanted into subcutaneous sites of subsequent recipient NOD/SCID mice without human FBs (NOD/SCID-hu(-)), and all but one grew successfully. Two of the EMTs have been maintained in the animal model for more than 12 months. The NOD/SCID-hu(+) chimeric animal model is highly efficient for growth of primary MCs and presents clinical features of human MM. The engrafted MCs can be maintained subsequently in NOD/SCID-hu(-) mice as in vivo culture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742278      PMCID: PMC1602249          DOI: 10.1016/S0002-9440(10)63162-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.

Authors:  Linda M Pilarski; Karen Seeberger; Robert W Coupland; Alana Eshpeter; Jonathan J Keats; Brian J Taylor; Andrew R Belch
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

Review 2.  New insights into role of microenvironment in multiple myeloma.

Authors:  Guido J Tricot
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.

Authors:  S Yaccoby; J Epstein
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

4.  Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model.

Authors:  T Rème; E Gueydon; C Jacquet; B Klein; J Brochier
Journal:  Br J Haematol       Date:  2001-08       Impact factor: 6.998

5.  The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.

Authors:  Richard B Lock; Natalia Liem; Monica L Farnsworth; Christopher G Milross; Chengyuan Xue; Mayamin Tajbakhsh; Michelle Haber; Murray D Norris; Glenn M Marshall; Alison M Rice
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks.

Authors:  A J Szczepek; A R Belch; L M Pilarski
Journal:  Exp Hematol       Date:  2001-09       Impact factor: 3.084

7.  Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone.

Authors:  T Reiman; K Seeberger; B J Taylor; A J Szczepek; J Hanson; M J Mant; R W Coupland; A R Belch; L M Pilarski
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

8.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

9.  Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.

Authors:  S Y Huang; J L Tang; S T Jou; W Tsay; C H Hu; D T Lin; K S Lin; K S Lin; C H Wang; Y C Chen; M C Shen; H F Tien
Journal:  Leukemia       Date:  1999-10       Impact factor: 11.528

10.  Human AML cells in NOD/SCID mice: engraftment potential and gene expression.

Authors:  R Lumkul; N-C Gorin; M T Malehorn; G T Hoehn; R Zheng; B Baldwin; D Small; S Gore; D Smith; P S Meltzer; C I Civin
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

View more
  8 in total

1.  Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Authors:  Daphne de Jong; Siegfried Janz
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

Review 2.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

Review 3.  Pathogenesis and treatment of multiple myeloma.

Authors:  Peipei Yang; Ying Qu; Mengyao Wang; Bingyang Chu; Wen Chen; Yuhuan Zheng; Ting Niu; Zhiyong Qian
Journal:  MedComm (2020)       Date:  2022-06-02

4.  Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.

Authors:  Shang-Yi Huang; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Hsin-An Hou; Wen-Chien Chou; Sheng-Chieh Chou; Szu-Chun Hsu; Bor-Sheng Ko; Hsiao-Yun Lu; Woei Tsay; Hwei-Fang Tien
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

5.  Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Chung-Wu Lin; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Yao-Chang Chen; Hsiao-Yun Lu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Sheng-Je Chou; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

6.  Precision mouse models with expanded tropism for human pathogens.

Authors:  Angela Wahl; Chandrav De; Maria Abad Fernandez; Erik M Lenarcic; Yinyan Xu; Adam S Cockrell; Rachel A Cleary; Claire E Johnson; Nathaniel J Schramm; Laura M Rank; Isabel G Newsome; Heather A Vincent; Wes Sanders; Christian R Aguilera-Sandoval; Allison Boone; William H Hildebrand; Paul A Dayton; Ralph S Baric; Raymond J Pickles; Miriam Braunstein; Nathaniel J Moorman; Nilu Goonetilleke; J Victor Garcia
Journal:  Nat Biotechnol       Date:  2019-08-26       Impact factor: 54.908

7.  Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.

Authors:  Andrei A Postnov; Henk Rozemuller; Viviene Verwey; Henk Lokhorst; Nora De Clerck; Anton C Martens
Journal:  Calcif Tissue Int       Date:  2009-10-09       Impact factor: 4.333

8.  Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.

Authors:  Taynah I P David; Otto L D Cerqueira; Marlous G Lana; Ruan F V Medrano; Aline Hunger; Bryan E Strauss
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.